X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement, Pluri will focus on the development of PLX-PAD cells (emiplacel), that exhibit immune-modulating capabilities, for the treatment of patients with cocaine addictions.
Lead Product(s): Emiplacel
Therapeutic Area: Psychiatry/Psychology Product Name: PLX-PAD
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bar-Ilan University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2024
Details:
The net funding will be used to advance the development of its PLX-R18 cell therapy as a potential novel treatment for Hematopoietic Acute Radiation Syndrome (H-ARS).
Lead Product(s): PLX-R18
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: PLX-R18
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Funding July 11, 2023
Details:
The goal of the PROTO project is to utilize Pluri’s PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).
Lead Product(s): PLX-PAD
Therapeutic Area: Musculoskeletal Product Name: PLX-PAD
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: European Union’s Horizon Europe
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 06, 2022
Details:
Patients treated with PLX-PAD (allogeneic PLX-PAD Cell) showed an increase of 2.3kg from reference (week 6) to week 26 compared to 0.51kg in the placebo group, a 1.8kg difference (p=0.073).
Lead Product(s): Allogeneic PLX-PAD Cell
Therapeutic Area: Musculoskeletal Product Name: PLX-PAD
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients. PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.
Lead Product(s): PLX-R18
Therapeutic Area: Immunology Product Name: PLX-R18
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
PLX-PAD cells demonstrated statistically significant superiority, in ability to increase muscle strength and volume for patients who have undergone total hip replacement surgery due to osteoarthritis.
Lead Product(s): PLX-PAD
Therapeutic Area: Musculoskeletal Product Name: PLX-PAD
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
The analysis will be based on 89 patients enrolled in the previously announced two Phase II studies, which investigated the safety and efficacy of Pluristem’s PLX cells as a treatment for severe COVID-19 cases complicated by ARDS.
Lead Product(s): PLX-PAD
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLX-PAD
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2021
Details:
The results demonstrate that PLX-R18 has the potential to stimulate the implanted hematopoietic cells to realize their therapeutic potential and generate improved blood counts over the long term in all three blood cell lineages at once.
Lead Product(s): PLX-R18
Therapeutic Area: Genetic Disease Product Name: PLX-R18
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
Based on the review, the DMC concluded that the CLI study is unlikely to meet the primary endpoint by the time of the final analysis. Company to terminate the CLI study of PLX-PAD to focus on different therapeutic areas in its pipeline.
Lead Product(s): PLX-PAD
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PLX-PAD
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Pluristem Therapeutics has received approval from the Israeli Ministry of Health to commence patient enrollment in Israel for its COVID-19 Phase II clinical trial, under the protocol that was approved by Germany’s regulatory agency.
Lead Product(s): PLX-PAD
Therapeutic Area: Infections and Infectious Diseases Product Name: PLX-PAD
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
